Last reviewed · How we verify
placebo pills and injectables
Placebo pills and injectables contain no active pharmaceutical ingredient and work through the placebo effect, wherein patient expectation and the clinical context produce therapeutic benefit independent of pharmacological action.
Placebo pills and injectables contain no active pharmaceutical ingredient and work through the placebo effect, wherein patient expectation and the clinical context produce therapeutic benefit independent of pharmacological action. Used for Clinical trial control / comparator, Conditions responsive to placebo effect (e.g., pain, nausea, fatigue).
At a glance
| Generic name | placebo pills and injectables |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert formulations used as controls in clinical trials and, in some clinical contexts, to harness the psychobiological placebo response. The therapeutic effect arises from patient expectation, conditioning, and the therapeutic relationship rather than from direct molecular interaction with disease pathways. Placebo responses can involve real neurobiological changes including endogenous opioid release and modulation of pain perception and other symptoms.
Approved indications
- Clinical trial control / comparator
- Conditions responsive to placebo effect (e.g., pain, nausea, fatigue)
Common side effects
- Nocebo effect (adverse events attributed to placebo)
Key clinical trials
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women (EARLY_PHASE1)
- Hormonal Mechanisms of Sleep Restriction - Axis Study (PHASE1)
- Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder (NA)
- MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes (PHASE1)
- Triple Therapy in T1DM (PHASE2, PHASE3)
- ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme (PHASE2)
- ACL Repair and Multimodal Analgesia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo pills and injectables CI brief — competitive landscape report
- placebo pills and injectables updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI